# 体外诊断液体活检测试市场

> 体外诊断液体活检测试市场研究报告，按测试类型（循环肿瘤细胞、循环肿瘤DNA、外泌体）、按应用（癌症检测、治疗监测、复发监测）、按最终用户（医院、诊断实验室、研究机构）、按技术（下一代测序、聚合酶链反应、微阵列）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 14.12%
- **2024:** $ 9.93 Billion
- **2025:** $ 11.33 Billion
- **2035:** $ 42.45 Billion
- **Key Players:** Guardant Health (US), Exact Sciences (US), Freenome (US), GRAIL (US), Biocept (US), Sysmex Corporation (JP), Roche Diagnostics (CH), Thermo Fisher Scientific (US), Qiagen (DE)

**Report ID:** MRFR/MED/35977-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/in-vitro-diagnostic-liquid-biopsy-testing-market-37932

---

## Market Summary

## **In Vitro Diagnostic Liquid Biopsy Testing Market Overview**

As per MRFR analysis, the In Vitro Diagnostic Liquid Biopsy Testing Market Size was estimated at 9.93 (USD Billion) in 2024. The In Vitro Diagnostic Liquid Biopsy Testing Market Industry is expected to grow from 11.33 (USD Billion) in 2025 to 37.20 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 14.12% during the forecast period (2025 - 2034).

## **Key In Vitro Diagnostic Liquid Biopsy Testing Market Trends Highlighted**

The In Vitro Diagnostic Liquid Biopsy Testing Market is experiencing significant growth driven by advancements in technology, increasing prevalence of cancer, and a rising focus on early detection methods. The demand for non-invasive diagnostic tools is propelling the adoption of liquid biopsy tests, as they provide a simpler alternative to traditional biopsy procedures. Furthermore, the increasing investments in R by key players aim to improve test accuracy and reliability, fostering market expansion. Awareness among patients and healthcare providers about the benefits of liquid biopsies also contributes to market growth. There are substantial opportunities to explore in this emerging market.

As the healthcare landscape evolves, integrating liquid biopsy testing into routine clinical practice can enhance patient outcomes. Developing innovative biomarkers and creating tailored tests for specific cancers represent significant avenues for growth. Additionally, partnerships between technology firms and healthcare companies can lead to new product offerings that meet the demands of both clinicians and patients. Expanding access to these tests in developing regions presents further opportunities as awareness and adoption rates are expected to increase. Recent trends indicate a shift towards personalized medicine, with liquid biopsy testing playing a crucial role in tailoring treatment plans for patients.

The rise in biomarker discovery and advancements in sequencing technologies are facilitating more accurate and comprehensive testing solutions. Furthermore, an increase in regulatory approvals for liquid biopsy products is expected to boost market confidence. Collaborations between academia and industry are also becoming more common, leading to innovative solutions and improved patient care. Overall, the liquid biopsy testing landscape is poised for significant transformation, driven by technological advancements and a commitment to improving the diagnostic process.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **In Vitro Diagnostic Liquid Biopsy Testing Market Drivers**

Technological Advancements in Liquid Biopsy Techniques

The In Vitro Diagnostic Liquid Biopsy Testing Market Industry is significantly driven by rapid advancements in technology that enhance liquid biopsy methodologies. Innovations in genomic sequencing, multi-omics approaches and digital pathology have revolutionized the detection of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes and other biomarkers from blood samples. These advancements not only improve the sensitivity and specificity of tests but also ensure that results are obtained more quickly, allowing for timely clinical decisions.

The development of point-of-care devices and the integration of artificial intelligence for data analysis further optimize the workflow, making it easier for healthcare providers to interpret complex data and offer personalized treatment plans. As technologies continue to evolve, the efficiency and reliability of liquid biopsy tests increase, bolstering confidence among healthcare professionals and patients alike. This creates a positive cycle of adoption and innovation within the In Vitro Diagnostic Liquid Biopsy Testing Market, facilitating its growth as methods become more accessible, cost-effective, and user-friendly.Consequently, this technological momentum is expected to contribute significantly to the market's expansion.

Increasing Incidence of Cancer

The burgeoning incidence of various cancer types globally acts as a crucial driver in the In Vitro Diagnostic Liquid Biopsy Testing Market Industry. As cancer continues to be a leading health issue, the demand for effective diagnostic tools is on the rise. Liquid biopsy tests facilitate early detection, monitoring and therapy response assessment, which are essential components in cancer treatment. This surge in demand for early and non-invasive diagnostic solutions encourages healthcare providers, researchers, and organizations to invest in liquid biopsy technologies, propelling market growth significantly.

Supportive Regulatory Frameworks

Another significant driver for the In Vitro Diagnostic Liquid Biopsy Testing Market Industry is the establishment of supportive regulatory frameworks. Many regulatory agencies are increasingly recognizing the importance of liquid biopsy tests in clinical practice and are adapting their guidelines to facilitate faster approval processes.

This supportive environment encourages more companies to invest in the research and development of innovative liquid biopsy solutions, knowing that their products are likely to receive timely validation and market entry.As a result, the industry witnesses a flood of new products aimed at addressing the clinical demands for accurate and efficient diagnostic solutions, thereby stimulating market growth.

## **In Vitro Diagnostic Liquid Biopsy Testing Market Segment Insights**

### **In Vitro Diagnostic Liquid Biopsy Testing Market Test Type Insights**

The In Vitro Diagnostic Liquid Biopsy Testing Market showcases a significant expansion in the Test Type segment, which includes vital components such as Circulating Tumor Cells, Circulating Tumor DNA and Exosomes. In 2023, the overall market was valued at 7.63 USD Billion, with an impressive upward trajectory leading to an expected valuation of 25.0 USD Billion by 2032, reflecting increasing reliance on non-invasive testing methods in oncology.

Circulating Tumor Cells, holding a market valuation of 2.5 USD Billion in 2023, dominate this segment due to their critical role in cancer diagnostics and treatment monitoring, allowing healthcare providers to evaluate tumor characteristics without invasive biopsies.

Following closely is Circulating Tumor DNA, valued at 3.0 USD Billion in 2023; this test type benefits from its ability to detect genetic mutations that inform targeted therapies, making it increasingly significant in precision medicine. Exosomes contribute with a valuation of 2.13 USD Billion in 2023 but show potential for growth in the future, as these extracellular vesicles are pivotal in cell-to-cell communication and may provide biomarkers for a wide range of diseases beyond cancer.

The growth drivers for this market segment include the rising prevalence of cancer, technological advancements in diagnostic tools, and the demand for personalized and minimally invasive testing methods.

However, challenges such as regulatory hurdles and the high cost of advanced testing technologies may impact market accessibility. Overall, the In Vitro Diagnostic Liquid Biopsy Testing Market segmentation continues to reflect a strong demand for innovative solutions in cancer care, with significant opportunities for expansion in the coming years.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **In Vitro Diagnostic Liquid Biopsy Testing Market Applications Insights**

The Applications segment plays a pivotal role in this market, with a major emphasis on Cancer Detection, Treatment Monitoring, and Recurrence Monitoring. Cancer Detection remains crucial as early diagnosis enhances treatment effectiveness, driving a significant portion of the market growth. Meanwhile, Treatment Monitoring is essential for assessing patient responses to therapies, providing valuable data that informs clinical decisions.

Recurrence Monitoring enables healthcare professionals to detect potential cancer relapses at an early stage, improving patient outcomes. Collectively, these applications contribute to the increased demand and value within the In Vitro Diagnostic Liquid Biopsy Testing Market. As the industry evolves, technological advancements and a growing preference for non-invasive testing methods are expected to fuel market growth. However, challenges such as regulatory hurdles and the need for standardization persist in the market landscape. 

Overall, the In Vitro Diagnostic Liquid Biopsy Testing Market data reflects a robust growth trajectory, underscored by advancements and a focus on precision medicine in cancer care.

### **In Vitro Diagnostic Liquid Biopsy Testing Market End User Insights**

The In Vitro Diagnostic Liquid Biopsy Testing Market is poised for substantial growth, particularly within the End User segment. Their facilities often utilize advanced technologies and possess the infrastructure necessary for extensive testing, leading to a significant share of the market. Diagnostic laboratories also play a vital role, serving as centers for accurate and timely testing services, which supports the increasing demand for liquid biopsy procedures.Research institutions contribute significantly by innovating and enhancing methodologies, thus fostering advancements in the liquid biopsy testing landscape. 

Collectively, these entities create a robust ecosystem that addresses the evolving needs within the In Vitro Diagnostic Liquid Biopsy Testing Market. The market growth is further supported by the rising prevalence of cancer and the demand for minimally invasive testing methods. However, challenges such as regulatory complexities and the need for standardized procedures may impact expansion.

Nevertheless, opportunities remain as advancements in technology and increased awareness around early cancer detection propel the market forward. The In Vitro Diagnostic Liquid Biopsy Testing Market statistics reflect a compelling drive toward improved patient outcomes and enhanced diagnostic precision in this evolving industry.

### **In Vitro Diagnostic Liquid Biopsy Testing Market Technology Insights**

The In Vitro Diagnostic Liquid Biopsy Testing Market within the Technology segment is projected to play a crucial role in enhancing patient diagnostics and treatment options.. Key technologies such as Next Generation Sequencing (NGS) are considered to significantly advance personalized medicine by enabling comprehensive genomic analysis, thereby improving the precision of cancer monitoring and treatment response evaluation.Additionally, Polymerase Chain Reaction (PCR) remains a prominent technique due to its rapid results and high sensitivity, valuable for detecting various types of cancerous markers.

Microarray technology, although less talked about, offers substantial utility in analyzing gene expression and genetic variations, supporting the evolution of targeted therapies. 

The combination of these technologies forms a robust foundation for the overall market growth, driven by factors such as rising cancer prevalence, technological advancements and increased funding in research.Furthermore, the In Vitro Diagnostic Liquid Biopsy Testing Market data reveals a rich landscape of advancements that could redefine standard practices in oncology and other fields.

### **In Vitro Diagnostic Liquid Biopsy Testing Market Regional Insights**

The In Vitro Diagnostic Liquid Biopsy Testing Market is experiencing significant growth across various regions, with North America leading with a valuation of 3.2 USD Billion in 2023, expected to rise to 12.0 USD Billion by 2032, thus holding a majority share. This domination is attributed to advanced healthcare infrastructure and increasing demand for non-invasive testing methods. Europe follows closely with a valuation of 2.5 USD Billion in 2023, projected to reach 8.5 USD Billion by 2032, driven by rising investments in cancer diagnostics and personalized medicine.

The APAC region is witnessing growth as well, with a value of 1.7 USD Billion in 2023 and a predicted increase to 3.8 USD Billion by 2032, reflecting a growing awareness of liquid biopsy's potential in cancer care. South America, while smaller in scale with a valuation of 0.8 USD Billion in 2023 and expected to grow to 1.4 USD Billion by 2032, is gradually adopting liquid biopsy technologies, demonstrating potential for future advancements.

Lastly, the MEA region, with a valuation of 0.43 USD Billion in 2023, is expanding the market, emphasizing the need for accessible diagnostic solutions as it moves towards 0.8 USD Billion by 2032.

Overall, the In Vitro Diagnostic Liquid Biopsy Testing Market data presents a dynamic and evolving landscape influenced by increasing awareness, technological advancements and the rising need for effective cancer diagnostics across these regions, highlighting both opportunities and challenges in this growing industry.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**In Vitro Diagnostic Liquid Biopsy Testing Market Key Players and Competitive Insights:**

The In Vitro Diagnostic Liquid Biopsy Testing Market has seen substantial growth in recent years, driven by advancements in technology and increasing demand for less invasive diagnostic methods. Liquid biopsy testing, which allows the detection of cancerous cells and genetic material from bodily fluids, is revolutionizing patient care by offering early diagnosis, monitoring treatment efficacy, and minimizing the need for traditional tissue biopsies. 

The competitive landscape of this market is characterized by a variety of players, ranging from established biotech firms to innovative startups, all aiming to capitalize on the growing prevalence of cancer and the need for efficient diagnostic solutions. As the market expands, competition intensifies, with companies focusing on enhancing their product offerings, improving accuracy, and expanding their presence in emerging markets.

Roche has established itself as a prominent player in the In Vitro Diagnostic Liquid Biopsy Testing Market, leveraging its extensive research and development capabilities to deliver high-quality diagnostic solutions. The company has strategically positioned itself through a robust portfolio of liquid biopsy tests, which are integrated with advanced technologies that enhance the precision of cancer detection and monitoring. Roche's renowned reputation for innovation, coupled with its commitment to improving patient outcomes, allows it to maintain a significant market presence. 

Additionally, the company’s collaborations with academic institutions and healthcare providers further enhance its role as a leader in the market, allowing it to tap into emerging trends and expand its product offerings effectively. Roche's focus on personalized medicine also resonates well with the increasing demand for tailored treatments, further solidifying its strengths within this niche segment of the market.

BristolMyers Squibb has been actively involved in the In Vitro Diagnostic Liquid Biopsy Testing Market, focusing on the integration of liquid biopsy solutions into its portfolio of oncology products. The company’s commitment to advancing cancer care through innovative diagnostic testing aligns with its mission of developing breakthrough therapies. 

BristolMyers Squibb’s strength lies in its strategic partnerships and collaborations that enhance its research initiatives, driving development in liquid biopsy technologies. By prioritizing biomarker discovery and patient stratification, the company ensures that its diagnostic offerings not only support treatment decisions but also contribute to improving patient outcomes. 

The emphasis on precision oncology reflects BristolMyers Squibb's understanding of the evolving landscape of cancer treatment, positioning it favorably amid increasing competition in the liquid biopsy space. Its ability to leverage data analytics and scientific expertise further enhances its credibility and presence in this rapidly growing market.

**Key Companies in the In Vitro Diagnostic Liquid Biopsy Testing Market Include**

**In Vitro Diagnostic Liquid Biopsy Testing Market Industry Developments**

The In Vitro Diagnostic Liquid Biopsy Testing Market has seen significant recent developments, particularly during the third quarter of 2023. Companies such as Roche and Illumina are at the forefront, focusing on advancements in non-invasive testing technologies to enhance cancer detection. Bristol-Myers Squibb has been exploring partnerships that expand their liquid biopsy capabilities, aligning with emerging precision medicine goals. Biocept and Exact Sciences continue to innovate with enhanced diagnostic solutions, driving competition in the liquid biopsy segment.

Moreover, Thermo Fisher Scientific has unveiled new platforms aimed at improving the accuracy and efficiency of liquid biopsy tests. Notably, Guardant Health has garnered attention for strategic collaborations aimed at expanding market reach. Several companies, including Qiagen and Sysmex, have also been rumored to pursue mergers or acquisitions to bolster their product offerings. The market is experiencing growth in valuation, driven by the increasing adoption of liquid biopsy testing in oncology, fueling demand for more sophisticated testing solutions and influencing investment strategies among key players.

This surge is reflective of a broader trend toward personalized medicine, enhancing the significance of liquid biopsies in clinical practice.

## **In Vitro Diagnostic Liquid Biopsy Testing Market Segmentation Insights**

### **In Vitro Diagnostic Liquid Biopsy Testing Market Test Type Outlook**

### **In Vitro Diagnostic Liquid Biopsy Testing Market Applications Outlook**

### **In Vitro Diagnostic Liquid Biopsy Testing Market End User Outlook**

### **In Vitro Diagnostic Liquid Biopsy Testing Market Technology Outlook**

### **In Vitro Diagnostic Liquid Biopsy Testing Market Regional Outlook**

## Market Drivers

### 癌症发病率上升

全球癌症发病率的上升是体外诊断液体活检市场的主要驱动力。随着癌症发病率的持续上升，对有效和及时的诊断解决方案的需求变得愈加迫切。液体活检提供了一种有前景的替代传统方法的选择，能够更早地检测和更好地监测治疗反应。根据最近的统计数据，预计未来二十年癌症病例将增加约70%，这可能会显著增加对液体活检测试的需求。这个不断增长的患者群体为市场参与者在液体活检领域创新和扩展其产品提供了可观的机会。

### 监管支持和批准

监管机构在体外诊断液体活检测试市场中发挥着至关重要的作用，提供明确的指导方针和加快创新诊断测试的审批流程。FDA和EMA等机构的支持正在促进一个有利于液体活检技术开发和商业化的环境。最近对各种癌症的液体活检测试的批准增强了制造商和医疗服务提供者的信心。这种监管支持预计将促进市场增长，因为它鼓励对研究和开发的投资。获批测试数量的增加可能会扩大市场，使液体活检成为肿瘤学中的标准实践。

### 增加对癌症研究的投资

对癌症研究的投资正在激增，这对体外诊断液体活检市场产生了积极影响。各国政府、私营组织和制药公司正在分配大量资源来开发先进的诊断工具，包括液体活检。这一资金的涌入正在促进新生物标志物和技术的探索，从而增强液体活检的能力。随着研究的进展，液体活检在提供肿瘤动态和治疗效果的全面见解方面的潜力变得越来越清晰。预计研究资金的增长将加速液体活检技术的采用，进一步推动市场增长。

### 液体活检测试中的技术进步

体外诊断液体活检测试市场正在经历快速的技术进步，这些进步提高了癌症检测的准确性和效率。下一代测序（NGS）和数字PCR的创新使得以空前的灵敏度识别循环肿瘤DNA（ctDNA）成为可能。这些进展不仅改善了诊断能力，还促进了个性化治疗方案的发展。预计市场将显著增长，估计在未来几年复合年增长率（CAGR）将超过20%。随着技术的不断发展，液体活检取代传统组织活检的潜力变得越来越可行，从而推动市场扩张。

### 对非侵入性检测的需求日益增长

在体外诊断液体活检测试市场中，对非侵入性测试方法的需求显著增加。患者和医疗服务提供者越来越倾向于液体活检，因为它们能够减少与传统活检相关的痛苦和风险。这种偏好的转变是由于对早期癌症检测和监测益处的日益认识。市场数据显示，液体活检细分市场预计将占据整体诊断市场的显著份额，预计到2027年，它可能占据超过30%的肿瘤诊断市场。这一趋势凸显了液体活检在癌症管理中成为基石的潜力。

## Future Outlook

体外诊断液体活检测试市场预计将在2024年至2035年间以14.12%的年复合增长率增长，推动因素包括技术进步和对非侵入性诊断的需求增加。

**New opportunities:**

- 开发基于人工智能的分析平台，以提高诊断准确性。 与医疗服务提供者扩展合作关系，以实现综合测试解决方案。 投资于研发新型生物标志物，以多样化产品供应。

到2035年，市场预计将强劲，反映出显著的增长和创新。

## Segment Insights

### 按测试类型：循环肿瘤细胞（最大）与循环肿瘤DNA（增长最快）

在体外诊断液体活检测试市场中，测试类型细分市场主要由循环肿瘤细胞（CTCs）主导，CTCs已确立为市场上最大的份额。这一细分市场对患者管理至关重要，并提供了肿瘤生物学的重要见解。相比之下，循环肿瘤DNA（ctDNA）迅速获得关注，成为一种强有力的替代方案，补充CTCs在非侵入性诊断程序中的应用。此外，外泌体虽然目前市场份额较小，但由于其在生物标志物发现和个性化医疗中的潜力，正受到越来越多的关注。

测试类型：CTCs（主导）与 ctDNA（新兴）

循环肿瘤细胞（CTCs）在体外诊断液体活检测试市场中至关重要，因为它们提供了癌症进展和治疗反应的实时洞察。由于在临床应用中的可靠性，CTCs受到强烈偏爱，提供监测治疗效果和早期发现转移的解决方案。另一方面，循环肿瘤DNA（ctDNA）代表了一项快速发展的新兴技术，因其敏感性和检测基因突变的能力而受到推动。ctDNA在肿瘤学中越来越受欢迎，因为它在液体活检中的潜力以及在微小残留病检测中的适用性。这两个领域在个性化癌症治疗中发挥着至关重要的作用，提升了患者的治疗效果。

### 按应用：癌症检测（最大）与治疗监测（增长最快）

在体外诊断液体活检测试市场中，应用领域主要由癌症检测驱动，该领域占据了最大的市场份额。该领域包括用于识别患者癌细胞或基因突变的各种技术。相反，治疗监测和复发监测是新兴领域，反映出对个性化医疗和持续患者管理的日益重视。治疗监测依赖于评估患者对治疗的反应，而复发监测则专注于早期检测癌症复发。

癌症检测（主导）与治疗监测（新兴）

癌症检测在体外诊断液体活检市场中成为主导应用，因为它在早期诊断中的关键作用以及全球癌症发病率的不断上升。该细分市场利用先进技术识别血液样本中的恶性细胞，从而简化诊断过程。另一方面，治疗监测迅速成为一个关键领域，利用液体活检评估肿瘤基因在治疗反应中的变化，提供治疗效果的实时洞察。这两个细分市场在市场中都处于良好位置，但满足患者管理中的不同需求。

### 按最终用户：医院（最大）与诊断实验室（增长最快）

体外诊断液体活检测试市场按最终用户细分，主要包括医院、诊断实验室和研究机构。在这些用户中，医院由于其丰富的资源、患者数量和提供广泛诊断服务的能力，拥有最大的市场份额。诊断实验室紧随其后，其显著份额归因于其对测试和分析的专业化关注，并得益于该领域自动化和技术的进步。

医院（主导）与诊断实验室（新兴）

医院在体外诊断液体活检测试市场中作为主要的终端用户细分市场。它们庞大的基础设施和患者网络促进了先进液体活检测试的整合到常规临床实践中。医院配备了进行各种诊断程序所需的工具和训练有素的人员，使其在癌症诊断和监测中发挥关键作用。另一方面，诊断实验室作为新兴细分市场，以其快速采用创新技术和专注于细分测试市场为特征。这些实验室利用尖端方法，通常与生物技术公司合作，以增强其服务产品，从而提高效率和快速周转时间。

### 按技术：下一代测序（最大）与聚合酶链反应（增长最快）

在体外诊断液体活检测试市场中，技术细分领域主要由下一代测序（NGS）主导，因其高灵敏度和同时分析多个基因的能力而确立了领先地位。紧随其后的是聚合酶链反应（PCR），因其精确性和在临床环境中的广泛应用而占有重要份额。微阵列技术虽然也相关，但在市场中的地位相对较小，强调了该细分市场内的竞争动态。

技术：下一代测序（主导）与聚合酶链反应（新兴）

下一代测序（NGS）被认为是体外诊断液体活检测试市场的主导技术，因其在全面基因组分析方面的无与伦比的能力。这种方法能够同时检测多种基因突变和改变，使其在个性化医学应用中不可或缺。相比之下，聚合酶链反应（PCR）正在迅速崛起，得益于提升其效率和准确性的进展。虽然PCR在靶向扩增DNA序列方面特别有效，但其与液体活检方法的日益整合正在推动其增长。这些技术的竞争演变继续重塑诊断领域，反映出向更精确和高效的恶性肿瘤检测的趋势。

## Regional Market Share Analysis

### 北美：创新的市场领导者

北美是体外诊断液体活检测试的最大市场，占全球市场份额的约45%。该地区的增长受到癌症发病率上升、技术进步和支持性监管框架的推动。FDA对多种液体活检测试的批准催化了市场扩展，增强了患者对非侵入性诊断选项的获取。美国在市场中处于领先地位，Guardant Health、Exact Sciences和GRAIL等关键企业推动了创新。竞争格局的特点是对研发的重大投资，各公司专注于扩展其产品组合。加拿大也显示出潜力，随着对先进诊断解决方案需求的上升，推动了该地区的整体增长。

### 欧洲：具有潜力的新兴市场

欧洲正在见证体外诊断液体活检测试的显著增长，约占全球市场份额的30%。该地区的增长受到对早期癌症检测意识的提高、医疗基础设施的进步以及欧洲药品管理局的支持性法规的推动。德国和英国等国处于前沿，推动对创新诊断解决方案的需求。德国是欧洲最大的市场，其次是英国，竞争格局中有Roche Diagnostics和Qiagen等关键企业。成熟的医疗系统和持续的研究计划进一步促进了市场增长。欧洲市场的特点是生物技术公司与研究机构之间的合作，增强了新型液体活检技术的发展。

### 亚太地区：快速增长的市场

亚太地区正在成为体外诊断液体活检测试快速增长的市场，约占全球市场份额的20%。该地区的增长受到癌症发病率上升、医疗支出增加和对早期诊断日益重视的推动。中国和日本等国正在引领潮流，政府倡议支持增强癌症筛查项目。中国是该地区最大的市场，在医疗技术方面进行了重大投资，生物技术行业蓬勃发展。日本紧随其后，Sysmex Corporation等成熟公司为市场增长做出了贡献。竞争格局正在演变，本地和国际参与者争夺市场份额，促进液体活检技术的创新与合作。

### 中东和非洲：未开发的市场潜力

中东和非洲代表了体外诊断液体活检测试的未开发市场，约占全球市场份额的5%。该地区的增长受到对癌症筛查意识的提高、医疗基础设施的改善和对生物技术投资的增加的推动。南非和阿联酋等国开始采用液体活检技术，政府倡议旨在增强癌症护理。南非是该地区最大的市场，越来越多的医疗机构采用先进的诊断解决方案。竞争格局仍在发展中，本地和国际参与者都有机会进入市场。随着对液体活检测试的意识和获取的改善，该地区在未来几年有望实现显著增长。

## Competitive Benchmarking

体外诊断液体活检测试市场目前的特点是动态竞争格局，受到技术进步和对非侵入性诊断解决方案需求增加的推动。主要参与者如Guardant Health（美国）、Exact Sciences（美国）和Roche Diagnostics（瑞士）处于前沿，各自采用不同的策略来增强市场定位。Guardant Health（美国）专注于基因组测试的创新，特别是通过其Guardant360测试，该测试因其能够从单次抽血中检测多种癌症类型而受到关注。与此同时，Exact Sciences（美国）强调战略合作伙伴关系，以扩大其产品供应和市场覆盖，特别是在结直肠癌筛查方面。Roche Diagnostics（瑞士）利用其广泛的研究能力，将液体活检解决方案整合到其更广泛的诊断产品组合中，从而增强其竞争优势。

这些公司的商业策略反映出一种共同努力，以优化运营并适应市场需求。例如，随着公司寻求降低成本和改善交付时间，本地化制造和优化供应链变得越来越重要。市场结构似乎适度分散，多个参与者争夺主导地位，但像Guardant Health和Roche Diagnostics这样的主要公司的集体影响表明，随着公司寻求增强其技术能力和市场份额，整合趋势正在加剧。

在2025年8月，Guardant Health（美国）宣布与一家领先的制药公司合作，开发一项旨在个性化癌症治疗的伴随诊断测试。这一战略举措可能会通过将其创新测试能力与日益增长的个性化医疗趋势对齐，从而增强Guardant在市场中的地位，提高患者结果，并可能增加收入来源。

在2025年9月，Exact Sciences（美国）推出了一种新的[液体活检](/zh-cn/reports/liquid-biopsy-market-710)测试，旨在检测早期癌症，这可能会显著影响患者管理和治疗路径。这一举措不仅强调了Exact对创新的承诺，还将公司定位为早期检测领域的关键参与者，而这一领域在肿瘤学中越来越受到重视。

在2025年7月，Roche Diagnostics（瑞士）通过收购一家专注于下一代测序技术的初创公司，扩大了其液体活检产品组合。这一收购表明了Roche增强其技术能力并将尖端解决方案整合到现有产品线中的战略，从而巩固其在市场中的竞争地位。

截至2025年10月，体外诊断液体活检测试市场的竞争趋势越来越受到数字化、可持续性和人工智能整合的影响。战略联盟变得越来越普遍，因为公司认识到合作在推动创新和扩大市场覆盖方面的价值。展望未来，竞争差异化将越来越依赖于技术进步和供应链可靠性，而不仅仅是价格。这一转变表明，创新和提供可靠、高质量的诊断解决方案的能力将在获得竞争优势方面至关重要。

## Recent News & Developments

体外诊断液体活检测试市场在2023年第三季度经历了显著的发展。罗氏和Illumina等公司处于前沿，专注于非侵入性测试技术的进步，以增强癌症检测。百时美施贵宝一直在探索扩展其液体活检能力的合作伙伴关系，以符合新兴的精准医疗目标。Biocept和Exact Sciences继续通过增强的诊断解决方案进行创新，推动液体活检领域的竞争。

此外，赛默飞世尔科技推出了旨在提高液体活检测试准确性和效率的新平台。值得注意的是，Guardant Health因其旨在扩大市场覆盖范围的战略合作而受到关注。包括Qiagen和Sysmex在内的几家公司也被传闻正在寻求合并或收购，以增强其产品供应。市场估值正在增长，推动因素是液体活检测试在肿瘤学中的日益普及，推动对更复杂测试解决方案的需求，并影响主要参与者的投资策略。

这种激增反映了向个性化医疗的更广泛趋势，增强了液体活检在临床实践中的重要性。

## Report Scope

| 2024年市场规模 | 9.928（十亿美元） |
| --- | --- |
| 2025年市场规模 | 11.33（十亿美元） |
| 2035年市场规模 | 42.45（十亿美元） |
| 年复合增长率（CAGR） | 14.12%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 关键公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 关键市场机会 | 非侵入性检测技术的进步增强了体外诊断液体活检测试市场的早期癌症检测。 |
| 关键市场动态 | 技术进步和监管变化推动体外诊断液体活检测试市场的增长。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 到2035年，体外诊断液体活检市场的预计市场估值是多少？**
A: 预计到2035年，市场估值将达到424.5亿美元。

**Q: 2024年体外诊断液体活检市场的市场估值是多少？**
A: 在2024年，市场估值为99.28亿美元。

**Q: 在2025年至2035年的预测期内，体外诊断液体活检测试市场的预期CAGR是多少？**
A: 在此期间，市场的预期CAGR为14.12%。

**Q: 在体外诊断液体活检测试市场中，哪些公司被视为关键参与者？**
A: 主要参与者包括 Guardant Health、Exact Sciences、Freenome、GRAIL、Biocept、Sysmex Corporation、Roche Diagnostics、Thermo Fisher Scientific 和 Qiagen。

**Q: 体外诊断液体活检测试的主要应用是什么？**
A: 主要应用包括癌症检测、治疗监测和复发监测。

**Q: 循环肿瘤DNA市场在估值方面表现如何？**
A: 循环肿瘤DNA部分在2024年的价值为40亿美元，预计到2035年将达到180亿美元。

**Q: 体外诊断液体活检测试市场中，诊断实验室部门的预期增长是多少？**
A: 诊断实验室部门在2024年的估值为40亿美元，预计到2035年将增长至180亿美元。

**Q: 推动体外诊断液体活检测试市场的技术有哪些？**
A: 关键技术包括下一代测序、聚合酶链反应和微阵列。

**Q: 到2035年，外泌体细分市场的预计估值是多少？**
A: 外泌体细分市场预计将从2024年的34.28亿美元增长到2035年的139.5亿美元。

**Q: 2025年，治疗监测市场与其他应用相比如何？**
A: 到2025年，治疗监测应用的预计价值为30亿美元，预计到2035年将增长至120亿美元。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/in-vitro-diagnostic-liquid-biopsy-testing-market-37932*